UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

March 6, 2007

Docket No. 03011672 License No. 45-16806-01
Control No. 140135

Susan Carroll
Chief Operating Officer
Loudoun Hospital Center
44045 Riverside Parkway
Leesburg, VA 20176

SUBJECT: LOUDOUN HOSPITAL CENTER, LICENSE AMENDMENT, CONTROL NO. 140135

Dear Ms. Carroll:

This refers to your license amendment request. Enclosed with this letter is the amended license. Please note that: (i) the Mentor sources are manufactured by Mills Biopharmaceuticals; (ii) licensed material under 10 CFR 31.11 has been listed under Dr. Krasicky's authorization; and (iii) unnecessary letters have been removed from the last condition of your license.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Current NRC regulations and guidance are included on the NRC's website at www.nrc.gov; select **Nuclear Materials; Medical, Industrial, and Academic Uses of Nuclear Material;** then **Toolkit Index Page.** Or you may obtain these documents by contacting the Government Printing Office (GPO) toll-free at 1-888-293-6498. The GPO is open from 7:00 a.m. to 9:00 p.m. EST, Monday through Friday (except Federal holidays).

Thank you for your cooperation.

Sincerely,

Original signed by Penny Lanzisera

Penny Lanzisera
Senior Health Physicist
Medical Branch
Division of Nuclear Materials Safety

Enclosure:
Amendment No. 25

cc:
Arnold M. Able, Radiation Safety Officer

DOCUMENT NAME: C:\FileNet\ML070660445.wpd

SUNSI Review Complete: PLanzisera
After declaring this document "An Official Agency Record" it **will** be released to the Public.

To receive a copy of this document, indicate in the box: "**C**" = Copy w/o attach/encl "**E**" = Copy w/ attach/encl "**N**" = No copy

OFFICE	DNMS/RI	N	DNMS/RI		DNMS/RI			
NAME	PLanzisera ***/PAN/***							
DATE	3/6/07							

OFFICIAL RECORD COPY

Amendment No. 25

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letter dated February 20, 2007,
1. Loudoun Hospital Center	3. License number 45-16806-01 is amended in its entirety to read as follows:
2. 44045 Riverside Parkway Leesburg, Virginia 20176	4. Expiration date February 28, 2013
	5. Docket No. 030-11672 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 600 millicuries
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed Sources (3M Model 6500 Series; AEA Technology Models CDC.S and CDC.TI; Best Medical Model 2301; Mills Biopharmaceuticals Model I-125 SL)	D. 300 millicuries
E. Any byproduct material permitted by 10 CFR 31.11	E. Prepackaged Kits	E. 3 millicuries

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
E. In vitro studies.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
45-16806-01

Docket or Reference Number
030-11672

Amendment No. 25

CONDITIONS

10. Licensed material may be used or stored only at the licensee's facilities located at 44045 Riverside Parkway, Leesburg, Virginia.

11. Licensed material is only authorized for use by, or under the supervision of:

    A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

    B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Gary A. Krasicky, M.D.	35.100; 35.200; 35.300; 31.11
Michael G. Velchik, M.D.	35.100; 35.200; 35.300
Brigid A. Castro, M.D.	35.100; 35.200; 35.300
Jonathan Eric Alfert, M.D.	35.100; 35.200; 35.300
Ingrid K. Schneider, M.D.	35.100; 35.200
J. Cullen Ruff, M.D.	35.100; 35.200
Jennifer H. Park, M.D.	35.100; 35.200
Patrick J. Oliverio, M.D.	35.100; 35.200
Gary M. Kellman, M.D.	35.100; 35.200
Nakul Jerath, M.D.	35.100; 35.200
Alex Hosong Lee, M.D.	35.100; 35.200
Lyndon K. Goodwin, M.D.	35.100; 35.200
James P. Earl, M.D.	35.100; 35.200
Charlene A. Curry, M.D.	35.100; 35.200
Rodney J. Butch, M.D.	35.100; 35.200
Ken Kin-Sing Au, M.D.	35.400

License Number
45-16806-01

Docket or Reference Number
030-11672

Amendment No. 25

MATERIALS LICENSE
SUPPLEMENTARY SHEET

12. The Radiation Safety Officer for this license is Arnold M. Able, M.S.

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application dated August 30, 2002 (ML030620574)
    B. Letter dated February 24, 2003 (ML030620569)
    C. Letter dated March 18, 2003 (ML030830441)
    D. Letter dated April 25, 2005 (ML051450086)

For the U.S. Nuclear Regulatory Commission

Date March 6, 2007

By ***Original signed by Penny Lanzisera***

Penny Lanzisera
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406